Company intelligence / Profile preview

GlycoMira Therapeutics

Salt Lake City, Utah, United Statesglycomira.com ↗

Ownership: Private
Development stage: Other

Overview

GlycoMira Therapeutics develops a new class of polysaccharide-based drugs that modulate the innate immune system. Their lead candidate, GM‑1111, has shown promising safety and efficacy in preclinical studies targeting solid tumors and supportive care needs such as radiation-induced mucosal injury. The company leverages NIH awards and private investment to advance its programs but has not yet reported late-stage clinical results.[1][4]

Therapeutic areas: OncologyPulmonologyGastroenterology
Modalities: Polysaccharide-based innate immune modulators[1]Small molecule drug (as per some pipeline listings)[4]
Industry: Biotech

Drug pipeline

1 asset

GM-1111

Preclinical

Partnerships

National Institutes of Health (grant funding/support)[1]

Beyond the preview

Go deeper on GlycoMira Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlycoMira Therapeutics.

Explore the full profile